Celyad SA
CYAD Healthcare Biotechnology
Celyad SA’s revenue for fiscal 2025 (year ended December 2025) was $23,800.00, down 88.2% from fiscal 2024.
Follow CYAD
Celyad SA (CYAD) Altman Z-score
Celyad SA's Altman Z-score for fiscal 2025 cannot be worked out: no share price in the week to the fiscal year end.
Altman Z-score, annual
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.39 | — | 0.47 | |
| Retained earnings / total assets | (84.54) | — | −118.36 | |
| EBIT / total assets | 0.20 | — | 0.68 | |
| Market value of equity / total liabilities | — | — | n/a | — |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | n/a — no share price in the week to the fiscal year end | — | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −270.29 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| EVAX Evaxion A/S - Sponsored ADR compare | −4.5× |
| IMMP Prima BioMed Ltd compare | −10.5× |
| MCRB Seres Therapeutics, Inc. compare | −11.0× |
| BYSI BeyondSpring Inc. compare | −12.5× |
| ABVC ABVC BioPharma, Inc. compare | −14.9× |
| ESLA Estrella Immunopharma, Inc. compare | — |
| PLRZ Polyrizon Ltd. compare | — |
| CNTX Context Therapeutics Inc. compare | — |
| CYAD Celyad SA | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets